Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 347-355

  Perentesis, John P ^a   Waddick, Kevin G ^a   Bendel, Anne E ^a   Shao, Yu ^a   Warman, Berta E ^a   Chandan Langlie, Mridula ^b   Uckun, Fatih M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; HYBRID PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RADIOSENSITIVITY;

ACUTE DISEASE; APOPTOSIS; DIPHTHERIA TOXIN; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE; RADIATION TOLERANCE; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030889068     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Wingo, P. A., long, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Schiffer, C. A. Acute myeloid leukemia in adults. In: J. F. Holland, E. Frei, R. C. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, p. 1907-1933. Philadelphia: Lea & Febiger, 1993.
3. Gottesman, M. M. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res., 53: 747-754, 1993.
4. Clift, R. A., Buckner, C. D., Appelbaum, F. R., Bearman, S. I., Petersen, F. B., Fisher, L. D., Anasetti, C., Beatty, P., Bensinger, W. I., Doney, K., Hill, R. S., McDonald, G. B., Martin, P., Sanders, J., Singer, J., Stewart, P., Sullivan, K. M., Witherspoon, R., Storb, R., Hansen, J. A., and Thomas, E. D. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood, 76: 1867-1871, 1990.
5. Geller, R. B., Saral, R., Piantadosi, S., Zahurak, M., Vogelsang, G. B., Wingard, J. R., Ambinder, R. F., Beschorner, W. B., Braine, H. G., Burns, W. H., Hess, A. D., Jones, R. J., Stratford-May, W., Rowley, S. D., Wagner, J. E., Yeager, A. M., and Santos, G. W. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood, 73: 2209-2218, 1989.
6. McGlave, P. B., Haake, R. J., Bostrom, B. C., Brunning, R., Hurd, D. D., Kirn, T. H., Nesbit, M. E., Vercellotti, G. M., Weisdorf, D., Woods, W. G., Ramsay, N. K. C., and Kersey, J. H. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood, 72: 1512-1517, 1988.
7. Perentesis, J. P., Miller, S. P., and Bodley, J. W. Protein toxin inhibitors of protein synthesis. Biofactors, 3: 173-184, 1992.
8. Van Ness, B. G., Howard, J. B., and Bodley, J. W. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J. Biol. Chem. 255: 10717-10720, 1980.
9. Naglich, J. G., Metherall, J. E., Russell, D. W., and Eidels, L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell, 69: 1051-1061, 1992.
10. Collier, R. J. Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A. Cancer Treat. Res., 37: 25-35, 1988.
11. Leong, D., Coleman, K. D., and Murphy, J. R. Cloned fragment A of diphtheria toxin is expressed and secreted into the periplasmic space of Escherichia coli K12. Science (Washington DC), 220: 515-517, 1983.
12. Kaczorek, M., Delpeyroux, F., Chenciner, N., Streeck, R. E., Murphy, J. R., Boquet, P., and Tiollais, P. Nucleotide sequence and expression of the diphtheria tox228 gene in Eschtrichia coli. Science (Washington DC), 221: 855-858, 1983.
13. Murphy, J. R. The diphtheria toxin structural gene. Curr. Top, Microbiol. Immunol., 118: 235-251, 1985.
14. Perentesis, J. P., Genbauffe, F. S., Veldman, S. A., Galeotti, C. L., Livingston, D. M., Bodley, J. W., and Murphy, J. R. Expression of diphtheria toxin fragment A and hormone-toxin fusion proteins in toxin-resistant yeast mutants. Proc. Natl. Acad. Sci. USA, 85: 8386-8390, 1988.
15. Murphy, J. R., Bishai, W., Borowski, M., Miyanohara, A., Boyd, J., and Nagle, S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. USA, 83: 8258-8262, 1986.
16. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B., and Murphy, J. R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng., 7: 493-498, 1987.
17. Jean, L. F., and Murphy, J. R. Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng., 4: 989-994, 1991.
18. Lakkis, F., Steele, A., Pacheco-Silva, A., Rubin-Kelley, V., Strom, T. B., and Murphy, J. R. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related m urine interleukin 4 fusion protein. Eur. J. Immunol., 21: 2253-2258, 1991.
19. Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M., Kantardjieff, K. A., Collier, R. J., and Eisenberg, D. The crystal structure of diphtheria toxin. Nature (Lond.), 357: 216-222, 1992.
20. Bennett, M. J., Choe, S., and Eisenberg, D. Domain swapping: entangling alliances between proteins. Proc. Natl. Acad. Sci. USA, 91: 3127-3131, 1994.
21. Diederichs, K., Boone, T., and Karplus, P. A. Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. Science (Washington DC), 254: 1779-1782, 1991.
22. Walter, M. R., Cook, W. J., Ealick, S. E., Nagabhushan, T. L., Trotta, P. P., and Bugg, C. E. Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. J. Mol. Biol., 224: 1075-1085, 1992.
23. Bazan, J. F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA, 87: 6934-6938, 1990.
24. Bendel, A. E., Shao, Y., Davies, S. M., Warman, B., Yang, C. H., Waddick, K. G., Uckun, F. M., and Perentesis, J. P. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leuk. & Lymphoma, in press, 1997.
25. Myers, D. E., Irvin, J. D., Smith, R. S., Kuebelbeck, V. M., and Uckun, F. M. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD 19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. Methods, 136: 221-237, 1991.
26. Collins, S. J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood, 70: 1233-1244, 1987.
27. Lozzio, C. B., Lozzio, B. B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood, 45: 321-334, 1975.
28. McGrath, T., Latoud, C., Arnold, S. T., Safa, A. R., Felsted, R. L., and Center, M. S. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol., 38: 3611-3619, 1989.
29. Marsh, W., Sicheri, D., and Center, M. S. Isolation and characterization of adriamycin-resistam HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res., 46: 4053-4057, 1986.
30. Krishnamachary, N., and Center, M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res., 53: 3658-3661, 1993.
31. Kreitman, R. J., Puri, R. K., and Pastan, I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc. Natl. Acad. Sci. USA, 91: 6889-6893, 1994.
32. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick. K. G., T-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 207: 886-891, 1995.
33. Uckun, F. M., Waddick, K. G., Mahajan, S., Jun, X., Takata, M., Bolen, J., and Kurosak, T. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science (Washington DC), 273: 1096-1100, 1996.
34. Park, L. S., Friend, D., Gillis, S., and Urdal, D. L. Characterization of the cell surface receptor for human granulocyte/macrophage colonystimulating factor. J. Exp. Med., 164: 251-262, 1986.
35. Kochi, S. K., and Collier, R. J. DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp. Cell Res, 208: 296-302, 1993.
36. Martin, S. J, Lennon, S. V., Bonham, A. M., and Cotter, T. G. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J. Immunol., 145: 1859-1867, 1990.
37. Vogelstein, B., Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
38. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med., 329: 1318-1327, 1993.
39. Chan, H. S., DeBoer, G., Thorner, P. S., Haddadm G., Gallic, B. L., and Ling, V. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol. Oncol. Clin. N. Am., 8: 383-410, 1994.
40. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222, 1993.
41. Licht, T., Pastan, I., Gottesman, M., and Herrmann, F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol., 69: 159-171, 1994.
42. Endicott, J. A., and Ling, V. The biochemistry of P-glycoproteinmediated multidrug resistance. Annu. Rev. Biochem. 58: 137-171, 1989.
43. Bhalla, K., Hindenburg, A., Taub. R. N., and Grant, S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res., 45: 3657-3662, 1985.
44. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 255: 1650-1654, 1992.
45. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79: 473-476, 1992.
46. Musto, P., Melillo, L., Lombardi, G., Matera, R., di Giorgio, G., and Carotenuto, M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol., 77: 50-53, 1991.
47. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H., and Lechner, K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst., 83: 708-712, 1991.
48. Marie, J. P., Zittoun, R., Sikic, B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78: 586-592, 1991.
49. Sato, H., Gottesman, M. M., Goldstein, L. J., Pastan, I., Block, A. M., Sandberg, A. A, and Preisler, H. D. Expression of the multidrug resistance gene in myeloid leukemias. Leuk. Res., 14: 11-21, 1990.
50. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M., and Pastan, I. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br. J. Haematol., 75: 340-345, 1990.
51. Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwanz, G. N., Karp, J. E., Burke, P. J., Kaufmann, S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85: 186-193, 1995.
52. Slapak, C. A., Mizunuma, N., and Kufe, D. W. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood, 84: 3113-3121, 1994.
53. Lowenberg, B., van Putten, W. L., Touw, I. P., Deiwel, R., and Santini, V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New Engl. J. Med., 328: 614-619, 1993.
54. Hunter, A. E., Rogers, S. Y., Roberts, I. A., Barrett, A. J., and Russell, N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood, 82: 899-903, 1993.
55. Young, D. C., and Griffin, J. D. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood, 68: 1178-1181, 1986.
56. Young, D. C., Wagner, K., and Griffin, J. D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J. Clin. Invest., 79: 100-106, 1987.
57. Russell, N. H. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev., 6: 149-156, 1992.
58. Griffin, J. D., Rambaldi, A., Vellenga, E., Young, D. C., Ostapovicz, D., and Cannistra, S. A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 70: 1218-1221, 1987.
59. Bradbury, D., Rogers, S., Reilly, I. A., Kozlowski, R., and Russell, N. H. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukaemia cells-studies using purified CD34-positive cells. Leukemia (Baltimore), 6: 562-566, 1992.
60. Bradbury, D., Bowen, G., Kozlowski, R., Reilly, I., and Russell, N. Endogenous interleukin-1 can regulate the autonomous growth of the blast cells of acute myeloblastic leukemia by inducing autocrine secretion of GM-CSF. Leukemia (Baltimore), 4: 44-47, 1990.
61. Rogers, S. Y., Bradbury, D., Kozlowski, R., and Russell, N. H. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp. Hematol., 22: 593-598, 1994.
62. Budel, L. M., Touw, I. P., Delwel, R., Clark, S. C., and Lowenberg, B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood, 74: 565-571, 1989.
63. Park, L. S., Waldron, P. E., Friend, D., Sassenfeld, H. M., Price, V., Anderson, D., Cosman, D., Andrews, R. G., Bernstein, I. D., and Urdal, D. L. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood, 74: 56-65, 1989.
64. Onetto-Pothier, N., Aumont, N., Haman, A., Park, L., Clark, S. C., De Lean, A., and Hoang, T. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act synergistically in supporting blast proliferation. Leukemia, 4: 329-336, 1990.
65. Onetto-Pothier, N., Aumont, N., Haman, A., Bigras, C., Wong, G. G., Clark, S. C., De Lean, A., and Hoang, T. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood, 75: 59-66, 1990.
66. Archimbaud, E., Fenaux, P., Reiffers, J., Cordonnier, C., Leblond, V., Travade, P., Troussard, X., Tilly, H., Auzanneau, G., Marie, J. P., Ffrench, M., and Berger, E. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia (Baltimore), 7: 372-377, 1993.
67. Valent, P., Sillaber, C., Geissler, K., Andreeff, M., Tafuri, A., Vieder, L., Schulz, G., Lechner, K., and Bettelheim, P. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Med. Pediatr. Oncoi., 2 (Suppl.): 18-22, 1992.
68. Bettelheim, P., Valent, P., Andreeff, M., Tafuri, A., Haimi, J., Gorischek, C., Muhm, M., Sillaber, C., Haas, O., Vieder, L., Maurer, D., Schulz, G., Speiser, W., Geissler, K., Kier, P., Himerberger, W., and Lechner, K. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 77: 700-711, 1991.
69. Cannistra, S. A., Groshek, P., and Griffin, J. D. Granulocytemacrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia (Baltimore), 3: 328-334, 1989.
70. Cannistra, S. A., DiCarlo, J., Groshek, P., Kanakura, Y., Berg, D., Mayer, R. J., and Griffin, J. D. Simultaneous administration of gran ulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia (Baltimore), 5: 230-238, 1991.
71. Estey, E., Thall, P. F., Kantarjian, H., O'Brien, S., Koller, C. A., Beran, M., Gutterman, J., Deisseroth, A., and Keating, M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood, 79: 2246-2255, 1992.
72. Kreitman, R. J., and Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.
73. Fitzgerald, D., and Pastan, I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann. NY Acad. Sci., 685: 740-145, 1993.
74. Fitzgerald, D. J., Willingham, M. C., Cardarelli, C. O., Hamada, H., Tsuruo, T., Gottesman, M. M., and Pastan, I. A monoclonal antibodyPseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA, 84: 4288-4292, 1987.
75. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
76. Wyllie, A. H. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br. J. Cancer, 67: 205-208, 1993.
77. Wyllie, A. H. The genetic regulation of apoptosis. Curr. Opin. Genet. & Dev., 5: 97-104, 1995.
78. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
79. Sachs, L., and Lotem, J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood, 82: 15-21, 1993.
80. Dive, C., and Hickman, J. A. Drug-target interactions: only the first step in the commitment lo a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
81. Kerr, J. F., Wimerford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
82. Hickman, J. A., Potten, C. S., Merritt, A. J., and Fisher, T. C, Apoptosis and cancer chemotherapy. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 345: 319-325, 1994.
83. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
84. Fan, S., el-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fomace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
85. Newcomb, E. W. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk. & Lymphoma, 17: 211-221, 1995.
86. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., and Fenaux, P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84: 3148-3157, 1994.
87. Wilson, B. A., Blanke, S. R., Murphy, J. R., Pappenheimer, A. M., Jr., Collier, R. J. Does diphtheria toxin have nuclease activity? Science (Washington DC), 250: 834-838, 1990.
88. Johnson, V. G. Does diphtheria toxin have nuclease activity? Science (Washington DC), 250: 832-833, 1990.
89. Bodley, J. W. Does diphtheria toxin have nucleate activity? Science (Washington DC), 250: 833-834, 1990.